Are you Dr. Creagan?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 68 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Summary
- Dr. Edward Creagan, MD is an oncologist in Rochester, Minnesota. He is currently licensed to practice medicine in Minnesota, Arizona, and Wisconsin. He is affiliated with Mayo Clinic Hospital - Rochester and is a Professor at Mayo Medical School.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1975 - 1977- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1973 - 1975
University of MichiganInternship, Internal Medicine, 1970 - 1971
New York Medical CollegeClass of 1970
Certifications & Licensure
MN State Medical License 1973 - 2025
AZ State Medical License 2013 - 2020
WI State Medical License 2010 - 2019- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System Start of enrollment: 2004 Jan 01
- Everolimus in Treating Patients With Stage IV Melanoma Start of enrollment: 2005 Apr 01
- Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2005 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 20 citationsPhase II study of tamoxifen in patients with disseminated malignant melanoma.Edward T. Creagan, James N. Ingle, Green Sj, David L. Ahmann, N S Jiang
Cancer Treatment Reports. 1980-02-01 - 67 citationsA preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on th...David L. Ahmann, Judith R. O'Fallon, Paul D. Scanlon, W.S. Payne, Harry F. Bisel
American Journal of Clinical Oncology. 1982-08-01 - 70 citationsNeuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma.Jeffrey T. Schleusener, Henry D. Tazelaar, Sin-Ho Jung, Stephen S. Cha, Peter J. Cera
Cancer. 1996-04-01
Press Mentions
The Matter of the Heart - Covid 19- Delta Variant - Dr. Edward T. CreaganAugust 23rd, 2021- Mayo Clinic Research in the News — 7/19/2021July 19th, 2021
- The World Has Changed. What Does That Mean for Veterinary Medicine?September 30th, 2020
- Join now to see all
Professional Memberships
- Member
